BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-12-14 06:43 |
BerGenBio to present at DNB Nordic Healthcare Conference 2021
|
English | 2.9 KB | ||
| 2021-12-13 14:00 |
BERGENBIO PRESENTS UPDATED BEMCENTINIB AML DATA AT ASH 2021 MEETING
|
English | 130.8 KB | ||
| 2021-12-13 14:00 |
BERGENBIO PRESENTS UPDATED BEMCENTINIB AML DATA AT ASH 2021 MEETING
|
English | 3.8 KB | ||
| 2021-11-17 16:51 |
BerGenBio ASA: Share capital increase
|
Norwegian | 89.9 KB | ||
| 2021-11-17 16:51 |
BerGenBio ASA: Share capital increase
|
English | 1.9 KB | ||
| 2021-11-16 06:00 |
BERGENBIO ASA: RESULTS FOR THE THIRD QUARTER OF 2021
|
English | 7.2 MB | ||
| 2021-11-16 06:00 |
BERGENBIO ASA: RESULTS FOR THE THIRD QUARTER OF 2021
|
English | 156.3 KB | ||
| 2021-11-16 06:00 |
BERGENBIO ASA: RESULTS FOR THE THIRD QUARTER OF 2021
|
English | 6.5 KB | ||
| 2021-11-09 15:29 |
BerGenBio ASA: Increase of share capital, exercise of share options
|
English | 90.9 KB | ||
| 2021-11-09 15:29 |
BerGenBio ASA: Increase of share capital, exercise of share options
|
English | 2.2 KB | ||
| 2021-11-09 13:05 |
BERGENBIO RECEIVES FDA FAST TRACK DESIGNATION FOR BEMCENTINIB IN STK11-MUTATED …
|
English | 178.8 KB | ||
| 2021-11-09 13:05 |
BERGENBIO RECEIVES FDA FAST TRACK DESIGNATION FOR BEMCENTINIB IN STK11-MUTATED …
|
English | 5.3 KB | ||
| 2021-11-09 13:00 |
BERGENBIO PRESENTS PRE-CLINICAL AND CLINICAL DATA ON BEMCENTINIB IN STK11-POSIT…
|
English | 171.5 KB | ||
| 2021-11-09 13:00 |
BERGENBIO PRESENTS PRE-CLINICAL AND CLINICAL DATA ON BEMCENTINIB IN STK11-POSIT…
|
English | 5.5 KB | ||
| 2021-11-04 14:11 |
BERGENBIO TO PRESENT UPDATED BEMCENTINIB AML DATA AT ASH 2021 MEETING
|
English | 131.4 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
